More evidence that warfarin is not being utilized enough

March 1997
Modern Medicine;Mar97, Vol. 65 Issue 3, p19
Focuses on a study by Lawrence M. Brass touting increased utilization of warfarin sodium in elderly patients with atrial fibrillation. Evidence that the anticoagulant lowers the risk of stroke; Association between atrial fibrillation and strokes in patients aged 80 and older.


Related Articles

  • Dabigatran vs Warfarin for AFib. Kuritzky, Louis // Primary Care Reports;Dec2010 Clinical Briefs, p24 

    This article discusses research being done on the efficacy and safety of dabigatran and warfarin in the prevention of stroke in atrial fibrillation, published in the journal "Lancet" in 2010.

  • Risk assessment for bleeding during warfarin therapy. Kuritzky, Louis // Internal Medicine Alert;12/15/2010 Supplement, p183 

    The article offers information on the role of the HAS-BLED stratification tool in evaluating one-year risk of bleeding in patients with atrial fibrillation (AF) who were undergoing warfarin therapy.

  • Warfarin Better for Atrial Fibrillation Patients. Elliott, William T. // Critical Care Alert;Aug2007 Pharmacology Watch, p2 

    The article reports on a study which found that warfarin is substantially more effective in preventing stroke in patients with nonvalvular atrial fibrillation than is antiplatelet therapy.

  • Warfarin vs Aspirin for Atrial Fibrillation in the Elderly. Crawford, Michael H. // Internal Medicine Alert;11/29/2007, Vol. 29 Issue 22, p170 

    Over half of patients with atrial fibrillation are over age 75 years, yet there is concern about the risk of serious hemorrhage in these patients on warfarin. Thus, the results of the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study are of interest. BAFTA was a prospective...

  • Gene-based Medicine - Prime Time Yet? Gupta, Rahul // Internal Medicine Alert;3/29/2009, Vol. 31 Issue 6, p42 

    The article offers study finding which shows that using genotyping for warfarin therapy in patients having non-valvular atrial fibrillation may not be cost-effective.

  • QOF should drive greater warfarin use.  // Pulse;3/24/2010, Vol. 70 Issue 10, p4 

    The article reports on the change needed on the outcomes and quality framework (QOF) indicators to drive more patients for greater warfarin use for atrial fibrillation in Great Britain.

  • Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Go, Alan S.; Hylek, Elaine M.; Go, A S; Hylek, E M; Borowsky, L H; Phillips, K A; Selby, J V; Singer, D E // Annals of Internal Medicine;12/21/99, Vol. 131 Issue 12, p927 

    Background: Warfarin dramatically reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambulatory patients with atrial fibrillation has not been widely studied.Objective: To assess the rates and predictors of warfarin use in...

  • Rivaroxaban vs. Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation. Darby-Stewart, Andrea; Dachs, Robert; Graber, Mark A. // American Family Physician;3/15/2012, Vol. 85 Issue 6, p581 

    A review of the article "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation," by M. R. Patel, J. Garg and colleagues, which appeared in the 2011 issue of the "New England Journal of Medicine," is presented.

  • Warfarin.  // Reactions Weekly;6/2/2012, Issue 1404, p41 

    The article describes the case of a 31-year-old woman who developed intracerebral haemorrhage after treatment with warfarin for atrial fibrillation and mitral valve replacement.

  • Warfarin.  // Reactions Weekly;9/1/2012, Issue 1417, p45 

    The article describes the case of a 72-year-old man who developed a haemothorax while being treated with warfarin for atrial fibrillation.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics